BRAF and melanoma: However, cobimetinib plus atezolizumab did not demonstrate a longer PFS than pembrolizumab alone in BRAF wild-type melanoma (5.5 vs. 5.7 months, respectively; p = 0.30), which showed that the combination of a MEK inhibitor and ICIs might not be more effective in these patients [125].